Jetstar to Charge for Overhead Cabin Bags From February 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
BOSTON, March 21, 2018 -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, is scheduled to present at the 17th Annual Needham & Company Healthcare Conference at the Westin New York Grand Central in New York City on Wednesday, March 28, 2018, at 9:30 a.m. EDT.
A live audio webcast of the presentation will be accessible from the Investors page of Albireo's website, ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo’s website for at least two weeks following the event.
For information about the conference, visit http://www.needhamco.com/conferences/needham-companys-17th-annual-healthcare-conference/.
About Albireo
Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis (PFIC). Albireo’s clinical pipeline also includes two Phase 2 product candidates. Albireo’s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Investor Contact:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568
Media Contact:
Sarah Hall
6 Degrees
215-313-5638
[email protected]
Source: Albireo Pharma, Inc.
